New drug combo aims to shrink bladder tumors before surgery

NCT ID NCT06059547

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 22 times

Summary

This study tests whether adding the experimental drug visugromab to standard immunotherapy can help shrink muscle-invasive bladder cancer before surgery. About 31 adults who cannot or choose not to receive cisplatin chemotherapy will receive the combination before having their bladder removed. The main goal is to see how many patients have no cancer left at the time of surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • A.O.U. Città della Salute e della Scienza di Torino

    Torino, 10126, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, 20133, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS, UOC Oncologia Medica

    Roma, 00168, Italy

  • IRCCS Ospedale San Raffaele Hospital Vita-Salute San Raffaele University

    Milan, 20132, Italy

Conditions

Explore the condition pages connected to this study.